Maternal and fetal outcomes after lamotrigine use in pregnancy: A retrospective analysis from an urban maternal mental health centre in New Zealand

Psychopharmacology Bulletin

Volumn 46, Issue 2, 2016, Pages 63-69

  Prakash, Chandni ^a   Hatters Friedman, Susan ^b   Moller Olsen, Charmian ^a   North, Abigail ^b  

^a AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bipolar disorder; Fetal and maternal outcomes; Lamotrigine; Mood stabilisers

Indexed keywords

ENALAPRIL; LAMOTRIGINE; NORTRIPTYLINE; OLANZAPINE; QUETIAPINE; CALCIUM CHANNEL BLOCKING AGENT; TRIAZINE DERIVATIVE;

ADULT; APGAR SCORE; ARTICLE; BIPOLAR DISORDER; CESAREAN SECTION; CONGENITAL MALFORMATION; DSM-IV-TR; FEMALE; FETUS OUTCOME; HUMAN; HYPERTENSION; LIVE BIRTH; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MATERNAL CARE; MATERNAL HYPERTENSION; MENTAL HEALTH CENTER; MENTAL HEALTH SERVICE; NEONATAL INTENSIVE CARE UNIT; NEW ZEALAND; NEWBORN; NEWBORN DISEASE; OBESITY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; RECURRENT DISEASE; RETROSPECTIVE STUDY; TRACHEOESOPHAGEAL FISTULA; UNSPECIFIED SIDE EFFECT; INFANT; MENTAL HEALTH; PREGNANCY COMPLICATION;

BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; INFANT; MENTAL HEALTH; NEW ZEALAND; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 85021349983     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and non-pregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157:179–184.
2. Briggs GC, Freeman RK, Yaffe SJ, eds. A Reference Guide to Fetal and Neonatal Risk. Drugs in Pregnancy and Lactation, 9th ed. Lipincott Williams and Wilkins; 2011.
3. Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet Part A. 2012;158A:2071–2090.
4. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170:1240–1247.
5. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: Pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6):709–713.
6. Zavodnick AD, Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatr Q Sept. 2012;83(3):371–383.
7. Wakil L, Epperson CN, Gonzalez J, O’Reardon JP, Kim DR. Neonatal outcomes with the use of Lamotrigine for Bipolar Disorder in Pregnancy and Breastfeeding: A case series and review of literature. Psychopharmacology Bull. 2009;42:91–98.
8. Cunnington M, Tennis P. International lamotrigine pregnancy registry scientific advisory committee. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64:955–960.
9. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193–198.